gene therapy leader’s stock poised for growth By Investing.com
Sarepta Therapeutics (NASDAQ:), a biotechnology company with a market capitalization of $12.06 billion specializing in RNA-targeted therapeutics for rare diseases, has positioned itself as a leader in the treatment of Duchenne muscular dystrophy (DMD) and is expanding its reach into other rare genetic disorders. With its flagship gene therapy Elevidys receiving expanded approval and a promising pipeline in development, Sarepta’s stock has garnered significant attention from investors and analysts alike. According to InvestingPro data, the company has demonstrated impressive revenue growth of 48.45% over the last twelve months, reflecting strong market momentum.
Company Overview and Market Position
Sarepta Therapeutics has established…
